Rallybio Corp. (RLYB) - Margin dodolan operasi

Rallybio Corporation (RLYB) - logo korporat

The operating profit margin chart for Rallybio Corporation (RLYB) is flattening due to the complexities of orphan drug approval and R&D expenditures. The company's foundation relies on the development of antibodies for the therapy of rare infant diseases. Current speculative risks and research costs are already priced in. The value of -4659.20 reflects this status, demonstrating the actual operating profit before tax deductions.

RLYB: Rentabilitas operasi Rallybio Corp 04.07.2022 - 20.11.2026

Rincian metrik lan analitis perusahaan Rallybio Corporation (RLYB)

- rega lan prakiraan konsensus rega:
- indikator kapitalisasi pasar:
Pambiji fundamental perusahaan:Rallybio Corp, RLYB
Barang utama Rallybio Corp.

To protect capital from volatility, it is crucial for investors to evaluate cost management efficiency via the operating margin. The monopoly position of Rallybio Corporation (RLYB) in the orphan drug segment guarantees stable demand, which is reflected in the operating profit margin as an indicator of the ability to generate earnings before interest and taxes, confirming the fundamental resilience of the asset within a portfolio.

Analisis perusahaan pesaing

Rentabilitas operasi haleon.com|Rentabilitas operasi KVUE|Rentabilitas operasi Verona Pharma (VRNA)|Jyong Biotech (MENS) - Tingkat bathi adhedhasar bathi operasi|Margin operasi LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Rentabilitas operasi|PRGO - Rentabilitas operasi|Alvotech Corp (ALVO) - Margin dodolan operasi|LQDA: Margin operasi|Rentabilitas dodolan operasi glpg.com (GLPG)|Rentabilitas operasi ANI Pharmaceuticals Inc|MNKD: Tingkat bathi operasi|Margin dodolan operasi AMPH (Amphastar)|PCRX - Rentabilitas dodolan operasi|Margin operasi SPRY (ars-pharma.com)|Tingkat bathi operasi TBPH|Aquestive Therapeutics, Inc. - Margin operasi|scpharmaceuticals.com - Rasio bathi operasi|Tectonic (TECX) - Rentabilitas operasi|Margin dodolan operasi Tonix Pharmaceuticals Inc.|Rentabilitas operasi sxtchina.com|Margin dodolan operasi Eupraxia Pharmaceuticals (EPRX)|Margin operasi BHST|EXOZ - Rentabilitas dodolan operasi|Oramed - Margin dodolan operasi|Entera Bio Ltd. (ENTX) - Rentabilitas dodolan operasi|HYFT - Rentabilitas operasi|ABVC: Rentabilitas operasi|CPIX: Margin operasi|Quantum BioPharma Ltd. - Tingkat bathi operasi|FGEN (FibroGen Corp) - Margin operasi|Telomir Pharma (TELO) - Rentabilitas kegiatan operasi|Rentabilitas operasi Rani Therapeutics Inc (RANI)|SNYR (Synergy CHC Corp.) - Tingkat bathi operasi|lexariabioscience.com - Margin dodolan operasi|Margin operasi Pulmatrix Inc PULM|Pheton Holdings - Margin operasi|Margin bathi operasi APM|Lyra Therapeutics, Inc. (LYRA) - Rentabilitas operasi|Rentabilitas dodolan operasi Impact BioMedical, Inc. (IBO)|Rentabilitas operasi TNF Pharma|YCBD: Tingkat bathi operasi|Margin operasi PRFX|CYTO - Rentabilitas dodolan operasi|Rentabilitas operasi Lipella LIPO|Rasio bathi operasi OPTN (OptiNose, Inc.)|PIRS - Rentabilitas operasi|Procaps (PROC) - Margin dodolan operasi|PTPI: Margin operasi|Qilian International (QLI) - Margin operasi|Rentabilitas operasi Acelyrin, Inc.|Margin operasi TFF Pharmaceuticals, Inc.